Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-01-01
2008-01-01
Kam, Chih-Min (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S006900, C514S008100, C514S012200, C530S350000, C530S400000, C435S004000, C435S252100, C435S252330
Reexamination Certificate
active
07314857
ABSTRACT:
A synergistic antimicrobial composition for inhibiting biofilm formation includes an iron-sequestering glycoprotein, a cationic polypeptide and a chelating agent, or an iron-sequestering glycoprotein and a chelating agent, or an iron-sequestering glycoprotein and a cationic polypeptide. Additionally, surfactants and quaternary ammonium compounds may also be advantageously combined with iron-sequestering glycoproteins in an antimicrobial composition. Methods of using a synergistic composition for inhibiting medical device biofilm formation are also disclosed.
REFERENCES:
patent: 5688516 (1997-11-01), Raad et al.
patent: 6267979 (2001-07-01), Raad et al.
patent: 2002/0001582 (2002-01-01), Charter et al.
patent: 2002/0141986 (2002-10-01), Lim et al.
patent: 2003/0148399 (2003-08-01), Nemori et al.
patent: 2284364 (2000-04-01), None
patent: 0629347 (1994-12-01), None
patent: WO 96/06532 (1996-03-01), None
Leitch et al. , Current Eye Research 19, 12-9 (Jul. 1999).
Ellison et al., J. Clin. Invest. 88, 1080-1091 (1991).
Johnson, Egg Uses and Processing Technologies (1994), 177-191, edited by J. S. Sim & S. Nakai.
Darouiche, R. et al., “Antimicrobial activity and durability of a novel antimicrobial-impregnated bladder catheter,”International Journal of Antimicrobial Agents, vol. 8, Issue 4, pp. 243-247—Abstract only (May 1997).
Schierholz J. et al., “Controlled release of antibiotics from biomedical polyurethanes morphological and structural features,”Biomaterials, vol. 18, No. 12, pp. 839-844—Abstract only (Jun. 1997).
Tunney, M. et al., “Infection associated with medical devices,”Reviews in Medical Microbiology, vol. 7, No. 4, pp. 195-205 (1996).
Bezkorovainy, A., “Antimicrobial properties of iron-binding proteins,”Adv. Exp. Med. Biol., vol. 135, pp. 139-154, Abstract only (1981).
Costerton, J. et al., “Bacterial Biofilms: A Common Cause of Persistent Infections,”Science, vol. 284, pp. 1318-1322 (May 21, 1999).
Darouiche, R. et al., “A comparison of two antimicrobial-impregnated central venous catheters. Catheter Study Group,”N. Engl. J. Med., vol. 340, No. 1, pp. 1-8, Abstract only (2 pages) (Jan. 7, 1999).
Darouiche, R. et al., “Antimicrobial activity of antiseptic-coated orthopaedic devices,”Int. J. Antimicrob. Agents, vol. 10, No. 1, pp. 83-86, Abstract only (Apr. 1998).
Donlan, R., “Biofilms and Device-Associated Infections,”Emerging Infectious Diseases, vol. 7, No. 2, pp. 277-281 (Mar.-Apr. 2001).
Fallgren, C. et al., “In vitro anti-staphylococcal activity of heparinized biomaterials bonded with combinations of rifampicin,”Zentralbl Bakteriol, vol. 287, No. 1-2, pp. 19-31, Abstract only (2 pages) (Jan. 1998).
Jackson, D. et al., “Biofilm Formation and Dispersal under the Influence of the Global Regulator CsrA ofEscherichia coli,”J. of Bacteriology, vol. 184, No. 1, pp. 290-301 (Jan. 2002).
Johnson, J. et al., “Activities of a Nitrofurazone-Containing Urinary Catheter and a Silver Hydrogel Catheter against Multidrug-Resistant Bacteria Characteristic of Catheter-Associated Urinary Tract Infection,”Antimicrobial Agents and Chemotherapy, vol. 43, No. 12, pp. 2990-2995 (Dec. 1999).
Jones, D. et al., “Physicochemical characterization of hexetidine-impregnated endotracheal tube poly(vinyl chloride) and resistance to adherence of respiratory bacterial pathogens,”Pharm. Res., vol. 19, No. 6, pp. 818-824, Abstract only (Jun. 2002).
Maki, D. et al., “Engineering Out the Risk of Infection with Urinary Catheters,”Emerging Infectious Diseases, vol. 7, No. 2, pp. 1-6 (Mar.-Apr. 2001).
Petrillo, V. et al., “A Case Report of Vascular Catheter-Associated Bacteremia caused byMycobacterium tuberculosisin a Non-Immunosuppressed Patient,”Rev. Inst. Med. trop. S. Paulo, vol. 41, No. 3, pp. 203-204 (May-Jun. 1999).
Raad, I. et al., “Minocycline and ethylenediaminetetraacetate for the prevention of recurrent vascular catheter infections,”Clin. Infect. Dis., vol. 25, No. 1, pp. 149-151, Abstract only (Jul. 1997).
Raad, I. et al., “Antimicrobial durability and rare ultrastructural colonization of indwelling central catheters coated with minocycline and rifampin,”Crit. Care Med., vol. 26, No. 2, pp. 219-224, Abstract only (2 pages) (Feb. 1998).
Schieroholz, J. et al., “The antimicrobial efficacy of a new central venous catheter with long-term broad-spectrum activity,”J. of Antimicrobial Chemotherapy, vol. 46, pp. 45-50 (2000).
Strickler, D., “Biomaterials to prevent nosocomial infections: is silver the gold standard?”Curr. Opin. Infect. Dis., vol. 13, No. 4, pp. 389-393, Abstract only (Aug. 2000).
Valenti et al., “Studies of the antimicrobial activity of ovotransferrin”,Int. J. Tissue React.5: 97-105 (1983) (abstract only).
International Preliminary Report on Patentability dated Feb. 27, 2006.
Kam Chih-Min
Kane Biotech Inc.
Merchant & Gould P.C.
LandOfFree
Synergistic antimicrobial compositions and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synergistic antimicrobial compositions and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synergistic antimicrobial compositions and methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2758306